View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 23, 2020

Novartis, Amneal, Apotex offer hydroxychloroquine for Covid-19

Novartis is set to donate up to 130 million doses of generic hydroxychloroquine to help fight the Covid-19 coronavirus infection that led to a global pandemic.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

Novartis is set to donate up to 130 million doses of generic hydroxychloroquine to help fight the Covid-19 coronavirus infection that led to a global pandemic.

Currently, hydroxychloroquine and a related drug, chloroquine are being trialled to treat Covid-19.

The move by Novartis is intended to support ongoing trials, with plans to explore the need for more studies.

Novartis will donate up to 130 million 200mg doses by the end of May, including its existing stock of 50 million 200mg doses.

In addition, the company plans to boost capacity to increase supply and meet global demand.

Novartis division Sandoz holds registration for hydroxychloroquine in the US. The company will seek regulatory authorisations in the US and Europe.

Meanwhile, Amneal Pharmaceuticals is increasing the production of hydroxychloroquine sulfate at its manufacturing sites to help address the pandemic.

The company expects to generate around 20 million tablets by mid-April. The tablets will be available in the US via the company’s retail and wholesale customers, as well as direct sales.

Canadian pharmaceutical company Apotex also announced plans to donate hydroxychloroquine for a study assessing the drug’s ability to prevent Covid-19 in front-line healthcare employees.

The study is being performed by the University Health Network and Unity Health (St Michael’s Hospital) in Toronto.

These announcements come after US President Donald Trump touted the drug at a press briefing.

However, the American Society of Health-System Pharmacists (ASHP) added hydroxychloroquine to its list of drugs in shortage on 19 March. ASHP said that four out of eight manufacturers are now in shortage.

Teva Pharmaceutical Industries, Mylan and Bayer also committed to providing the drug for Covid-19.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology